Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader MarketZacks Investment Research • 41m
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should KnowZacks Investment Research • 10/23/26
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to KnowZacks Investment Research • 10/23/26
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a BetZacks Investment Research • 10/21/26
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.The Motley Fool • 10/18/26
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 10/16/26
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending StockZacks Investment Research • 10/12/26
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026GlobeNewsWire • 10/08/26
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 10/06/26
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?Zacks Investment Research • 10/05/26
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026GlobeNewsWire • 10/02/26
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 09/29/26
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?The Motley Fool • 09/29/26
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's WhyZacks Investment Research • 09/25/26
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene EditingSeeking Alpha • 09/24/26
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/24/26
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon24/7 Wall Street • 09/23/26
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?The Motley Fool • 09/18/26